Concise Statement: GrimAge-derived epigenetic age acceleration, when deconvoluted for neuronal vs. glial cell-type proportions in CSF-derived cell-free DNA, will outperform single-tissue blood-based clocks in distinguishing early Alzheimer's disease from MCI and healthy aging with >85% sensitivity and specificity.
Mechanistic Rationale:
GrimAge incorporates plasma protein surrogates (including GDF-15, PAI-1, and smoking-related methylation signals) that are biologically proximal to neuroinflammatory and vascular aging cascades relevant to AD. CSF cell-free DNA carries fragments shed from neurons, astrocytes, and microglia that are differentially methylated during AD pathogenesis. By integrating GrimAge acceleration with deconvolution algorithms that parse cell-type contributions, the composite signal would reflect both the pace of brain-specific aging and the cellular source of that acceleration — a dimension unavailable to blood-only clocks.
Curated pathway from expert analysis
flowchart TD
A["GrimAge Acceleration<br/>Epigenetic Age Signal"]
B["CSF Cell-Free DNA<br/>Neuronal Glial Fragments"]
C["Cell-Type Deconvolution<br/>Proportions"]
D["Neuronal Proportion<br/>vs Glial Proportion"]
E["GrimAge Plus<br/>Cell-Type Composite"]
F["Early AD Stratification<br/>vs MCI vs Healthy"]
G[">85% Sensitivity<br/>Specificity"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No curated PDB or AlphaFold mapping for CSF yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CSF, DNA, MCI, GDF, PAI.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF GrimAge acceleration is a cell-type-resolved CSF biomarker for early AD, THEN CSF immune-cell deconvolution plus GrimAge residuals will classify MCI amyloid-positive participants versus amyloid-neg | Cell-type-adjusted CSF methylation GrimAge residual model reaches AUC >=0.75 for amyloid-positive MCI status. | — no observation — | pending | 0.57 |
| IF GDF/PAI-linked GrimAge components reflect early AD biology, THEN their CSF methylation module scores will predict 12-month p-tau181 increase of >=15% among MCI participants. | Top-quartile CSF GrimAge component score predicts >=15% higher annual p-tau181 rise than bottom quartile. | — no observation — | pending | 0.55 |